

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UM-06669

Serial No.: 10/002,802

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(See General Instructions, If Necessary)

Applicant: Michael D. Uhler

Filing Date: 11/02/2001

Group Art Unit: 1636

(37 CFR § 1.98(b))

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
QN	1	4,683,195	07/28/87	Mullis <i>et al.</i>	435	6	02/07/86
	2	4,683,202	07/28/87	Mullis <i>et al.</i>	435	91	10/25/85
	3	4,965,188	10/23/90	Mullis <i>et al.</i>	435	6	06/17/87
	4	5,352,605	10/04/94	Fraley <i>et al.</i>	435	240.4	10/28/93
	5	5,584,807	12/17/96	McCabe	604	71	01/20/95
	6	5,618,682	04/08/97	Scheirer	435	8	02/08/94
	7	5,674,713	10/17/97	McElroy <i>et al.</i>	435	69.7	06/02/95
	8	5,976,796	11/02/99	Szalay <i>et al.</i>	435	6	12/23/96
	9	6,074,859	09/13/00	Hirokawa <i>et al.</i>	435	189	07/08/98
	10	5,837,533	11/17/98	Boutin	435	320.1	07/28/94
	11	5,654,185	08/05/97	Palsson	435	235.1	06/07/97
	12	5,804,431	07/08/98	Palsson	435	235.1	03/13/97
	13	5,811,274	09/22/98	Palsson	435	172.2	12/09/94
	14	5,965,352	10/12/99	Stoughton	435	172.1	12/09/94
	15	5,998,136	12/7/99	Kamb	435	6	08/19/96
	16	6,060,240	5/9/00	Kamb <i>et al.</i>	435	6	12/13/96
	17	10/002,802		Uhler <i>et al.</i>			
QN	18	10/123,435		Uhler <i>et al.</i>			

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
QN	19	WO 95/14098	5/26/95	PCT				
	20	WO 01/20015	3/22/01	PCT				
	21	WO 99/51773	10/14/99	PCT				
	22	WO 00/05339	02/02/00	PCT				
	23	0900849	3/10/99	EP				
	24	WO 98/53103	11/26/98	PCT				
	25	WO 99/55886	11/04/99	PCT				
QN	26	WO 99/58664	11/18/99	PCT				

Examiner:

Date Considered:

6/21/04

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAR 08 2004

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-06669	Serial No.: 10/002,802
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (U.S. Patent and Trademark Office, If Necessary) (37 CFR § 1.98(b))				Applicant: Michael D. Uhler	
				Filing Date: 11/02/2001	Group Art Unit: 1636
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
QW	27	Amundson, et al., Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses, <i>Oncogene</i> , 18(24):3666 (1999)			
	28	Bally, et al., Biological barriers to cellular delivery of lipid-based DNA carriers, <i>Adv Drug Deliv Rev</i> , 38(3):291 (1999);			
	29	Baron, et al., Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes, <i>Proc Natl Acad Sci U S A</i> , 96(3):1013 (1999);			
	30	Bittner, et al., Data analysis and integration: of steps and arrows, <i>Nat Genet</i> , 22(3):213 (1999);			
	31	Boynton and AL, Control of 3T3 cell proliferation by calcium, <i>In Vitro</i> , 10(12 (1974);			
	32	Brown and Botstein, Exploring the new world of the genome with DNA microarrays, <i>Nat Genet</i> , 21(1 Suppl):33 (1999);			
	33	Brown, et al., Induction of alkaline phosphatase in mouse L cells by overexpression of the catalytic subunit of cAMP-dependent protein kinase, <i>J Biol Chem</i> , 265(22):13181 (1990);			
	34	Brunner, et al., Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus, <i>Gene Ther</i> , 7(5):401 (2000);			
	35	Cheng, Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin, <i>Hum Gene Ther</i> , 7(3):275 (1996);			
	36	Duggan, et al., Expression profiling using cDNA microarrays, <i>Nat Genet</i> , 21(1 Suppl):10 (1999);			
	37	Gill and Sanseau, Rapid in silico cloning of genes using expressed sequence tags (ESTs), <i>Biotechnol Annu Rev</i> , 5(25 (2000);			
	38	Graves, Powerful tools for genetic analysis come of age, <i>Trends Biotechnol</i> , 17(3):127 (1999)			
	39	Huang, et al., Identification and temporal expression pattern of genes modulated during irreversible growth arrest and terminal differentiation in human melanoma cells, <i>Oncogene</i> , 18(23):3546 (1999)			
	40	Iyer, et al., The transcriptional program in the response of human fibroblasts to serum, <i>Science</i> , 283(5398):83 (1999);			
	41	Mann, et al., Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues, <i>Proc Natl Acad Sci U S A</i> , 96(11):6411 (1999);			
	42	Mortimer, et al., Cationic lipid-mediated transfection of cells in culture requires mitotic activity, <i>Gene Ther</i> , 6(3):403 (1999);			
	43	Neumann, et al., Fundamentals of electroporative delivery of drugs and genes, <i>Bioelectrochem Bioenerg</i> , 48(1):3 (1999);			
	44	Ross, et al., Enhanced reporter gene expression in cells transfected in the presence of DMI-2, an acid nuclease inhibitor, <i>Gene Ther</i> , 5(9):1244 (1998);			
	45	Skena, et al., Quantitative monitoring of gene expression patterns with a complementary DNA microarray, <i>Science</i> , 270(5235):467 (1995);			
	46	Tseng, et al., Mitosis enhances transgene expression of plasmid delivered by cationic liposomes, <i>Biochim Biophys Acta</i> , 1445(1):53 (1999);			
	47	Wagner, et al., DNA-binding transferrin conjugates as functional gene-delivery agents: synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety, <i>Bioconjug Chem</i> , 2(4):226 (1991);			
	48	Watson and Akil, Gene chips and arrays revealed: a primer on their power and their uses, <i>Biol Psychiatry</i> , 45(5):533 (1999);			
	49	Young, Biomedical discovery with DNA arrays, <i>Cell</i> , 102(1):9 (2000)			
	50	Zenke, et al., Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells, <i>Proc Natl Acad Sci U S A</i> , 87(10):3655 (1990);			
	51	Zhu, et al., Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays, <i>Proc Natl Acad Sci U S A</i> , 95(24):14470 (1998)			
	52	Antonyak, et al., Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor, <i>J Biol Chem</i> , 273(5):2817 (1998);			
QW	53	Barila, et al., A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK, <i>Embo J</i> , 19(2):273 (2000);			
Examiner: <i>[Signature]</i>		Date Considered: 6/21/04			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

RECEIVED

MAR 08 2004

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-06669	Serial No.: 10/002,802
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Separate Sheet if Necessary)				Applicant: Michael D. Uhler	
				Filing Date: 11/02/2001	Group Art Unit: 1636
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
QW	54	Collins and Uhler, Cyclic AMP- and cyclic GMP-dependent protein kinases differ in their regulation of cyclic AMP response element-dependent gene transcription, <i>J Biol Chem</i> , 274(13):8391 (1999);			
	55	Frodin, et al., A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1, <i>Embo J</i> , 19(12):2924 (2000);			
	56	Frost, et al., Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins, <i>Embo J</i> , 16(21):6426 (1997);			
	57	Fuchs, et al., MEKK1/JNK signaling stabilizes and activates p53, <i>Proc Natl Acad Sci U S A</i> , 95(18):10541 (1998);			
	58	Gryz and Meakin, Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-independent cell survival and neuronal differentiation, <i>Oncogene</i> , 19(3):417 (2000);			
	59	Guan, et al., Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells, <i>J Biol Chem</i> , 273(44):28670 (1998);			
	60	Hansra, et al., Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes, <i>Biochem J</i> , 342 ( Pt 2):337 (1999);			
	61	Huggenvik, et al., Regulation of the human enkephalin promoter by two isoforms of the catalytic subunit of cyclic adenosine 3',5'-monophosphate-dependent protein kinase, <i>Mol Endocrinol</i> , 5(7):921 (1991);			
	62	Iglesias and Rozengurt, Protein kinase D activation by deletion of its cysteine-rich motifs, <i>FEBS Lett</i> , 454(1-2):53 (1999);			
	63	Kawai, et al., Mouse smad8 phosphorylation downstream of BMP receptors ALK-2, ALK-3, and ALK-6 induces its association with Smad4 and transcriptional activity, <i>Biochem Biophys Res Commun</i> , 271(3):682 (2000);			
	64	Kohn, et al., Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation, <i>J Biol Chem</i> , 271(49):31372 (1996);			
	65	Komeima, et al., Inhibition of neuronal nitric-oxide synthase by calcium/calmodulin-dependent protein kinase IIalpha through Ser847 phosphorylation in NG108-15 neuronal cells, <i>J Biol Chem</i> , 275(36):28139 (2000);			
	66	Kuno-Murata, et al., Augmentation of thyroid hormone receptor-mediated transcription by Ca2+/calmodulin-dependent protein kinase type IV, <i>Endocrinology</i> , 141(6):2275 (2000);			
	67	Leevers, et al., Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane, <i>Nature</i> , 369(6479):411 (1994);			
	68	Ling, et al., NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176, <i>Proc Natl Acad Sci U S A</i> , 95(7):3792 (1998);			
	69	Novak, et al., Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways, <i>Proc Natl Acad Sci U S A</i> , 95(8):4374 (1998);			
	70	Ohteki, et al., Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3, <i>J Exp Med</i> , 192(1):99 (2000);			
	71	Raingeaud, et al., MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway, <i>Mol Cell Biol</i> , 16(3):1247 (1996);			
	72	Robinson, et al., A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation, <i>Curr Biol</i> , 8(21):1141 (1998);			
	73	Takeda, et al., Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiation and survival of PC12 cells, <i>J Biol Chem</i> , 275(13):9805 (2000);			
	74	Wang, et al., Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal transduction, <i>J Biol Chem</i> , 272(36):22771 (1997);			
	75	Zang, et al., Association between v-Src and protein kinase C delta in v-Src-transformed fibroblasts, <i>J Biol Chem</i> , 272(20):13275 (1997)			
QW	76	Zimmermann, et al., PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit type I, <i>J Biol Chem</i> , 274(9):5370 (1999).			
Examiner:		Date Considered: 6/21/04			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

RECEIVED

MAR 08 2004

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: UM-06669

Serial No.: 10/002,802

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(See Section 1.98(b) if Necessary)


Applicant: Michael D. Uhler

Filing Date: 11/02/2001

Group Art Unit: 1636

(37 CFR § 1.98(b))

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

QW	77	Abravaya, et al., Heat shock-induced interactions of heat shock transcription factor and the human hsp70 promoter examined by in vivo footprinting, Mol Cell Biol, 11(1):586 (1991);
	78	Altmann, et al., Transcriptional activation by CTF proteins is mediated by a bipartite low-proline domain, Proc Natl Acad Sci U S A, 91(9):3901 (1994);
	79	Benbrook and Jones, Different binding specificities and transactivation of variant CRE's by CREB complexes, Nucleic Acids Res, 22(8):1463 (1994);
	80	Blackwell, et al., Sequence-specific DNA binding by the c-Myc protein, Science, 250(4984):1149 (1990)
	81	Boccaccio, et al., Induction of epithelial tubules by growth factor HGF depends on the STAT pathway, Nature, 391(6664):285 (1998);
	82	Cao, et al., Identification and characterization of the Egr-1 gene product, a DNA-binding zinc finger protein induced by differentiation and growth signals, Mol Cell Biol, 10(5):1931 (1990);
	83	Fisch, et al., An AP1-binding site in the c-fos gene can mediate induction by epidermal growth factor and 12-O-tetradecanoyl phorbol-13-acetate, Mol Cell Biol, 9(3):1327 (1989);
	84	Hale and Braithwaite, Identification of an upstream region of the mouse p53 promoter critical for transcriptional expression, Nucleic Acids Res, 23(4):663 (1995);
	85	Hariharan, et al., Delta, a transcription factor that binds to downstream elements in several polymerase II promoters, is a functionally versatile zinc finger protein, Proc Natl Acad Sci U S A, 88(21):9799 (1991)
	86	Hiscott, et al., Triggering the interferon response: the role of IRF-3 transcription factor, J Interferon Cytokine Res, 19(1):1 (1999);
	87	Kamps, et al., A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL, Cell, 60(4):547 (1990);
	88	Lam, et al., Cell-cycle regulation of human B-myb transcription, Gene, 160(2):277 (1995);
	89	Lernbecher, et al., Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation, Nature, 365(6448):767 (1993);
	90	Northrop, et al., Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex, J Biol Chem, 268(4):2917 (1993);
	91	Oh and Im, The p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity, Mol Cells, 10(4):386 (2000);
	92	Pani, et al., The restricted promoter activity of the liver transcription factor hepatocyte nuclear factor 3 beta involves a cell-specific factor and positive autoactivation, Mol Cell Biol, 12(2):552 (1992)
	93	Robbins, et al., Negative regulation of human c-fos expression by the retinoblastoma gene product, Nature, 346(6285):668 (1990);
	94	Treisman, The SRE: a growth factor responsive transcriptional regulator, Semin Cancer Biol, 1(1):47 (1990);
	95	Uchijima, et al., Tax proteins of human T-cell leukemia virus type 1 and 2 induce expression of the gene encoding erythroid-potentiating activity (tissue inhibitor of metalloproteinases-1, TIMP-1), J Biol Chem, 269(21):14946 (1994);
	96	Vinson, et al., Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding: prediction and rational design, Genes Dev, 7(6):1047 (1993).
	97	Ziauddin, J and Sabatini, DM (2001) Microarrays of cells expressing defined cDNAs. Nature 411: 107-110.
	98	Wagner, et al. (1992) Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle, Proc Natl Acad Sci U S A, 89(17):7934
QW	99	Wagner, et al. (1990) Transferrin-polylysine conjugates as carriers for DNA uptake into cells, Proc Natl Acad Sci U S A, 87(9):3410. Duplicate
Examiner: 		Date Considered: 6/21/04
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

RECEIVED

MAR 08 2004



FORM PTO-144 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-06669		Serial No.: 10/002,802	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))				Applicant: Michael D. Uhler			
				Filing Date: 11/02/2001		Group Art Unit: 1636	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
QW	1	6,544,790	04/08/03	Sabatini.	435	455	09/18/00
Examiner: <i>[Signature]</i>				Date Considered: 6/21/04			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							